Use of a compound containing a fused heterocyclic ring in the preparation of a medicament for the prevention or treatment of gastric ulcer
By using compounds with fused heterocyclic structures to covalently bind to H+-K+-ATPase, the side effects of existing gastric ulcer drugs have been addressed, effectively reducing gastric acid secretion and repairing gastric mucosal damage, thus providing a novel solution for anti-ulcer drugs.
CN122440633APending Publication Date: 2026-07-24GANNAN INST OF INNOVATION & TRANSLATIONAL MEDICINE
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GANNAN INST OF INNOVATION & TRANSLATIONAL MEDICINE
- Filing Date
- 2026-05-28
- Publication Date
- 2026-07-24
AI Technical Summary
Technical Problem
Existing medications for treating gastric ulcers have side effects during treatment and are difficult to cure completely, failing to effectively reduce gastric acid secretion and repair gastric mucosal damage.
Method used
Compounds containing fused heterocyclic structures are used as proton pump inhibitors. By covalently binding to H+-K+-ATPase, the enzyme is irreversibly inactivated, reducing gastric acid secretion, increasing gastric pH, and repairing gastric mucosal damage.
Benefits of technology
It significantly reduced gastric ulcer foci, alleviated bleeding and mucosal edema, and achieved an ulcer inhibition rate of 50.00%, providing a candidate compound for novel anti-ulcer drugs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122440633A_ABST
Abstract
The application discloses application of a compound containing a condensed heterocyclic structure in preparation of a medicine for preventing or treating gastric ulcer, and relates to the technical field of medicinal chemistry. It is found through a large amount of screening and verification that the compounds 8018-9590, G642-6944, L861-0480 and E844-1779 can significantly reduce ulcer foci, significantly reduce the degree of hemorrhage, and specifically reduce mucosal edema and other core pathological characteristics of gastric ulcer, and the ulcer inhibition rate reaches 50.00%. The application provides a new compound type for screening of a medicine for treating gastric ulcer, and provides an important candidate for development of a new anti-ulcer medicine.
Need to check novelty before this filing date? Find Prior Art